CY1122145T1 - Ανοσογονικη συνθεση για clostridium difficile - Google Patents
Ανοσογονικη συνθεση για clostridium difficileInfo
- Publication number
- CY1122145T1 CY1122145T1 CY20191101061T CY191101061T CY1122145T1 CY 1122145 T1 CY1122145 T1 CY 1122145T1 CY 20191101061 T CY20191101061 T CY 20191101061T CY 191101061 T CY191101061 T CY 191101061T CY 1122145 T1 CY1122145 T1 CY 1122145T1
- Authority
- CY
- Cyprus
- Prior art keywords
- clostridium difficile
- protein
- cdtb
- modify
- binding domain
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 241000193163 Clostridioides difficile Species 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108010010925 Clostridium actin-specific ADP-ribosyltransferase Proteins 0.000 abstract 2
- 230000002163 immunogen Effects 0.000 abstract 2
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1411306.2A GB201411306D0 (en) | 2014-06-25 | 2014-06-25 | Immunogenic composition |
| GB201411371A GB201411371D0 (en) | 2014-06-26 | 2014-06-26 | Immunogenic composition |
| PCT/EP2015/064324 WO2015197737A1 (en) | 2014-06-25 | 2015-06-25 | Clostridium difficile immunogenic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122145T1 true CY1122145T1 (el) | 2020-11-25 |
Family
ID=53498986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191101061T CY1122145T1 (el) | 2014-06-25 | 2019-10-09 | Ανοσογονικη συνθεση για clostridium difficile |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20170218031A1 (enExample) |
| EP (2) | EP3636278A3 (enExample) |
| JP (2) | JP6688233B2 (enExample) |
| CN (1) | CN106536544B (enExample) |
| BE (1) | BE1022949B1 (enExample) |
| BR (1) | BR112016030096B1 (enExample) |
| CA (1) | CA2952118A1 (enExample) |
| CY (1) | CY1122145T1 (enExample) |
| DK (1) | DK3160500T3 (enExample) |
| ES (1) | ES2749701T3 (enExample) |
| HR (1) | HRP20191864T1 (enExample) |
| HU (1) | HUE045936T2 (enExample) |
| LT (1) | LT3160500T (enExample) |
| MX (1) | MX374380B (enExample) |
| PL (1) | PL3160500T3 (enExample) |
| PT (1) | PT3160500T (enExample) |
| SI (1) | SI3160500T1 (enExample) |
| WO (1) | WO2015197737A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3595709A4 (en) * | 2017-03-15 | 2020-12-23 | Novavax, Inc. | METHODS AND COMPOSITIONS FOR INDUCING IMMUNE RESPONSES TO CLOSTRIDIUM DIFFICILE |
| JP7426953B2 (ja) | 2018-06-19 | 2024-02-02 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
| GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4866034A (en) | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US4436727A (en) | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US4877611A (en) | 1986-04-15 | 1989-10-31 | Ribi Immunochem Research Inc. | Vaccine containing tumor antigens and adjuvants |
| EP0362278A4 (en) | 1987-06-05 | 1990-05-14 | Us Health | Autocrine motility factors in cancer diagnosis and management. |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| DK0382271T3 (da) | 1989-02-04 | 1995-05-01 | Akzo Nobel Nv | Tocoler som adjuvanser i vacciner |
| ATE156710T1 (de) | 1992-06-25 | 1997-08-15 | Smithkline Beecham Biolog | Adjuvantien enthaltende impfstoffzusammensetzung |
| NZ263538A (en) | 1993-03-23 | 1996-10-28 | Smithkline Beecham Biolog | Vaccine compositions of 3-o-deacylated monophosphoryl lipid a |
| JP2002514886A (ja) | 1994-10-24 | 2002-05-21 | プロメガ コーポレーション | クロストリジウム・ディフィシル疾患の治療及び予防のためのワクチン及び抗トキシン |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| JPH11506332A (ja) | 1995-06-02 | 1999-06-08 | インサイト・ファーマスーティカルズ・インコーポレイテッド | 全長ｃＤＮＡ配列を獲得する改良された方法 |
| JP2002542169A (ja) * | 1999-04-09 | 2002-12-10 | テクラブ， インコーポレイテッド | Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン |
| WO2001073030A2 (en) | 2000-03-28 | 2001-10-04 | Diadexus, Inc. | Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer |
| WO2005004791A2 (en) * | 2002-11-08 | 2005-01-20 | President And Fellows Of Harvard College | Compounds and methods for the treatment and prevention of bacterial infection |
| IN2014CN04071A (enExample) * | 2011-12-08 | 2015-10-23 | Novartis Ag | |
| AR089797A1 (es) * | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| EP2928489B1 (en) * | 2012-12-05 | 2019-02-27 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| GB201223342D0 (en) * | 2012-12-23 | 2013-02-06 | Glaxosmithkline Biolog Sa | Immunogenic composition |
-
2015
- 2015-06-25 CA CA2952118A patent/CA2952118A1/en active Pending
- 2015-06-25 EP EP19192151.9A patent/EP3636278A3/en not_active Withdrawn
- 2015-06-25 BR BR112016030096-3A patent/BR112016030096B1/pt active IP Right Grant
- 2015-06-25 EP EP15733404.6A patent/EP3160500B1/en active Active
- 2015-06-25 HR HRP20191864TT patent/HRP20191864T1/hr unknown
- 2015-06-25 WO PCT/EP2015/064324 patent/WO2015197737A1/en not_active Ceased
- 2015-06-25 DK DK15733404T patent/DK3160500T3/da active
- 2015-06-25 PT PT157334046T patent/PT3160500T/pt unknown
- 2015-06-25 MX MX2016017094A patent/MX374380B/es active IP Right Grant
- 2015-06-25 CN CN201580039744.7A patent/CN106536544B/zh active Active
- 2015-06-25 LT LT15733404T patent/LT3160500T/lt unknown
- 2015-06-25 US US15/320,190 patent/US20170218031A1/en not_active Abandoned
- 2015-06-25 ES ES15733404T patent/ES2749701T3/es active Active
- 2015-06-25 BE BE2015/5390A patent/BE1022949B1/fr active
- 2015-06-25 SI SI201530954T patent/SI3160500T1/sl unknown
- 2015-06-25 JP JP2016575190A patent/JP6688233B2/ja active Active
- 2015-06-25 PL PL15733404T patent/PL3160500T3/pl unknown
- 2015-06-25 HU HUE15733404A patent/HUE045936T2/hu unknown
-
2019
- 2019-10-09 CY CY20191101061T patent/CY1122145T1/el unknown
-
2020
- 2020-01-17 JP JP2020005532A patent/JP2020100625A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3636278A3 (en) | 2020-07-15 |
| US20170218031A1 (en) | 2017-08-03 |
| JP2020100625A (ja) | 2020-07-02 |
| BE1022949B1 (fr) | 2016-10-21 |
| PT3160500T (pt) | 2019-11-11 |
| ES2749701T3 (es) | 2020-03-23 |
| CA2952118A1 (en) | 2015-12-30 |
| MX374380B (es) | 2025-03-06 |
| CN106536544B (zh) | 2020-04-07 |
| BR112016030096B1 (pt) | 2023-10-03 |
| HUE045936T2 (hu) | 2020-01-28 |
| DK3160500T3 (da) | 2019-11-11 |
| BE1022949A1 (fr) | 2016-10-21 |
| MX2016017094A (es) | 2017-05-03 |
| JP6688233B2 (ja) | 2020-04-28 |
| PL3160500T3 (pl) | 2020-02-28 |
| LT3160500T (lt) | 2019-10-25 |
| WO2015197737A1 (en) | 2015-12-30 |
| BR112016030096A2 (pt) | 2017-08-22 |
| EP3160500B1 (en) | 2019-08-21 |
| JP2017520573A (ja) | 2017-07-27 |
| HRP20191864T1 (hr) | 2020-01-10 |
| BR112016030096A8 (pt) | 2021-07-06 |
| CN106536544A (zh) | 2017-03-22 |
| EP3636278A2 (en) | 2020-04-15 |
| SI3160500T1 (sl) | 2019-11-29 |
| EP3160500A1 (en) | 2017-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124106T1 (el) | Συνθεσεις μεταφορεα-αντισωματος και μεθοδοι παρασκευης και χρησης αυτων | |
| DOP2021000022A (es) | Anticuerpos neutralizadores del virus de inmunodeficiencia humana | |
| CY1124131T1 (el) | Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου | |
| CO2018011804A2 (es) | Receptores quiméricos de flt3 y métodos de uso de los mismos | |
| CY1124979T1 (el) | Κατασκευασματα πρωτεϊνης uspa2 και χρησεις αυτων | |
| IL269830A (en) | Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response | |
| MX2022005202A (es) | Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos. | |
| BR112018005779A2 (pt) | repressores de htt e usos dos mesmos | |
| CL2018000042A1 (es) | Anticuerpos de unión a tau | |
| IL263846B (en) | Formulation of a peptide vaccine | |
| BR112016028891A2 (pt) | processos de trens de sementes e usos dos mesmos | |
| MX2017008191A (es) | Composiciones y metodos para anticuerpos dirigidos a bmp6. | |
| EA201790569A1 (ru) | Антитела и иммуноконъюгаты против cll-1 | |
| CL2018000043A1 (es) | Anticuerpos de unión a tau | |
| CY1124425T1 (el) | Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης | |
| MX371033B (es) | Productos farmacéuticos mejorados de péptido para resistencia a la insulina. | |
| EA201692002A1 (ru) | Стабильные составы для антител к cd19 и конъюгатов антитело-лекарственное средство | |
| SV2016005352A (es) | Anticuerpos antagonistas del interferon alfa y omega | |
| DK3199179T3 (da) | Formulering af rekombinant fusionsprotein | |
| CY1124727T1 (el) | Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων | |
| BR112015025748A2 (pt) | construção de dna para imunomodulação, composição farmacêutica, vacina, e uso de uma construção de dna | |
| CY1122145T1 (el) | Ανοσογονικη συνθεση για clostridium difficile | |
| CL2017001310A1 (es) | Péptidos cíclicos derivados de cd44v6 para el tratamiento de enfermedades relacionadas con cánceres y angiogénesis | |
| EP3534944A4 (en) | COMBINATION OF A LISTERIA-BASED VACCINE WITH ANTI-CTLA-4 OR ANTI-CD137 ANTIBODIES | |
| EP3475418A4 (en) | TATK-CDKL5 FUSION PROTEINS, COMPOSITIONS, FORMULATIONS AND THEIR USE |